We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Hormone Shows Promise for Treating Celiac Disease

By Biotechdaily staff writers
Posted on 27 Feb 2003
Results from a recent study suggest that a synthetic form of alpha-melanocyte-stimulating hormone (alpha-MSH) has an anti-inflammatory effect on celiac mucosa and may lead to the first medical treatment for celiac disease. More...
The study appeared in the February 20, 2003, issue of NeuroImmunoModulation.

Alpha-MSH is a naturally occurring molecule that modulates inflammatory and immune responses. Data confirming the presence of alpha-MSH in celiac mucosa suggest the presence of a local reaction of the molecule to control the inflammatory response elicited by gliadin. Gliadin is the subfraction of gluten that acts as a toxin in people with celiac disease, causing an immune reaction and resulting in damage to the small intestine.

"Our research suggests that locally produced alpha-SH modulates inflammation and perhaps limits epithelial damage in patients with celiac disease,” said James M. Lipton, Ph.D., study investigator and chief scientific officer of Zengen, Inc. (Woodland Hills, CA, USA). "We are particularly excited by these findings as these data, coupled with abundant evidence of the anti-inflammatory and anti-infective activity of Zengen's novel molecules based on alpha-MSH, further validate our research and development efforts in numerous areas, including celiac disease.”





Related Links:
Zengen

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
POC Immunoassay Analyzer
Procise DX
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.